Sign In
Buy TALS
$2.72
+0 (+0%)
At Close: Dec 14, 2023
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
05:37pm, Thursday, 19'th Oct 2023
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
05:47pm, Tuesday, 17'th Oct 2023
Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
05:09pm, Friday, 06'th Oct 2023
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Ta
This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organizatio
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Th
3 Hot Penny Stocks to Watch Before Next Week
03:40pm, Monday, 26'th Jun 2023
Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy whe
„MIR M: Vanguard & Vagabond“ – neues MMORPG von Wemade startet weltweit
12:37am, Wednesday, 01'st Feb 2023
SEOUL, Südkorea--(BUSINESS WIRE)--Wemade hat am 31. Januar 2023 offiziell sein MMORPG „MIR M: Vanguard & Vagabond“ (MIR M) in mehr als 170 Ländern der Welt eingeführt. „MIR M“ ist ein MMORP
DUBLIN--(BUSINESS WIRE)--The "Novel Spectrometry Platforms Market, 2022-2035: Distribution by Type of Spectrometers, Company Size, End User Industry, Key Geographical Regions: Industry Trends and Glob
Talaris (TALS) Down on Patient Death From Renal Transplant Study
12:48pm, Friday, 21'st Oct 2022
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
08:24am, Thursday, 20'th Oct 2022
Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplan
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
07:00am, Tuesday, 04'th Oct 2022
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
07:00am, Wednesday, 21'st Sep 2022
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transfor
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
07:00am, Tuesday, 06'th Sep 2022
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
07:59am, Monday, 29'th Aug 2022
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stoc
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transfor
